Novo Nordisk shares pop 10% on early-stage weight loss drug trial results – CNBC By Weight Loss Novo Nordisk shares pop 10% on early-stage weight loss drug trial results CNBC Next-gen Novo Nordisk shot shows 22% weight loss in early results Reuters Novo Nordisk Stock Soars on New Weight-Loss Drug Data. Eli Lilly Stock Falls. Barron’s Brought to you by Google News. Read the rest of the article here Facebook Twitter Pinterest